Phase 3 data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases demonstrated the safety and efficacy of seladelpar in patients with primary biliary cholangitis through 12 months of treatment.
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 Pliant Therapeutics, Inc. , a clinical-stage.